We’re here again, awaiting Amgen’s fourth-quarter and full-year 2023 results with bated breath, convinced that another win is inevitable. Following a solid earnings surprise of 6.67% in the last quarter, expectations are soaring high for yet another impressive performance. But, is the optimism justified? Let’s delve into the factors that could potentially make or break this quarter’s earnings.
Factors Driving Anticipation
Amgen’s anticipated product sales surge is largely attributed to robust volume growth in products such as Evenity, Repatha, Prolia, and Blincyto. Despite this, a decline in the prices of most products is expected to offset the gains. Forecasts for Prolia, Repatha, Evenity, and Blincyto sales are encouraging, with estimates projecting substantial revenues. The increasing demand for newer drugs like Tezspire and Tavneos is also expected to be a significant driving force, thanks to a surge in new patient volume. However, a decline in sales of oncology biosimilars and legacy established products is likely to dampen the earnings outlook.
Additionally, the impact of free drug programs and lowered pricing on Otezla sales, coupled with pricing pressure affecting Enbrel, remain looming concerns, while the recent acquisition of Horizon Therapeutics promises to augment Amgen’s portfolio. However, adjustments in earnings per share due to investments in pipeline candidates and interest expenses related to Horizon financing cast a shadow on the profitability forecast.
Historical Performance
Historically, Amgen has earned its stripes with a consistent four-quarter earnings surprise averaging 6.04%, indicating a resilient financial track record. In the wake of such a formidable history, expectations for another impressive performance are not irrational.
Potential for Surpassing Expectations
With Amgen’s Earnings ESP standing at +1.01%, and a current Zacks Rank of #3, our indicators are pointing towards an impending earnings beat. Subsequent to the reduced impact of free drug programs and strategic investments to bolster Otezla sales, signs of progress are becoming evident.
Industry Dynamics
It’s worth noting that Amgen’s stock has risen a commendable 23.9% over the past year, defying the industry’s downward trend, which saw a decrease of 14.1%. Such resilience in the face of industry headwinds stands as a testament to the company’s exceptional value proposition.
Comparative Market Analysis
As we eagerly await Amgen’s unveiling of their financial prowess, it’s imperative to keep an eye out for other pharma giants that may potentially outperform in this earnings season. Novartis, AstraZeneca, and Sanofi are exhibiting promising signs, with all set to release their quarterly results in the coming days.
In a nutshell, the stage is set for an eventful earnings announcement. The anticipation is rife; the stakes are high; and the momentum is palpable. All eyes are on Amgen as we take the plunge into yet another earnings spectacle. Let’s wait and watch if Amgen can keep up the tempo and once again emerge as the champion.
Zacks Investment Research: Top 7 Stocks Forecast for the Next 30 Days
Investors are eagerly eyeing the latest insightful recommendations from Zacks Investment Research. As experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys, they assert these tickers to be “Most Likely for Early Price Pops.”
Since 1988, the full list has outperformed the market, logging an impressive 2X over with an average gain of +24.0% per year. It’s no wonder that these hand-picked 7 demand immediate attention from potential investors.
Sanofi (SNY) : Free Stock Analysis Report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
Novartis AG (NVS) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
